Nephrology Medical News about renal-cell carcinoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Resistance to targeted therapy in renal-cell carcinoma
The Lancet Oncology, 10/01/09

Rini BI et al. – Therapeutic targeting of integral biological pathways, including those involving vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR), has produced robust clinical effects and revolutionised the treatment of metastatic renal–cell carcinoma (RCC). Clinical data support activity of several agents in resistant patient populations, with large–scale clinical trials ongoing to more thoroughly test several postulations regarding the optimum clinical approach.

<< Previous
Pharmacokinetics of moxifloxacin in patients undergoing...

Next >>
Low-dose indomethacin after ischemic acute kidney injury prevents...